Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31568826 | 1.00 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1GRIK1KMT2AMEN1 | |
| SCHEMBL1007327 | 0.88 | MAPT (0.49) | HSP90AA1HSP90AB1KMT2AMEN1PDK1 | |
| SCHEMBL3787046 | 0.86 | KMT2A (0.54) | HSP90AA1HSP90AB1KMT2AMEN1PDK1 | |
| SCHEMBL31738321 | 0.85 | GAA (0.44) | HSP90AA1HSP90AB1GRIK1KMT2AMEN1 | |
| SCHEMBL24509457 | 0.84 | AAK1 (0.48) | KMT2AMEN1GAAALDH1A1RAB9A | |
| SCHEMBL31021765 | 0.84 | HPGD (0.49) | KMT2AMEN1GAAMAPTALDH1A1 | |
| SCHEMBL1008737 | 0.84 | HPGD (0.49) | KMT2AMEN1GAAMAPTALDH1A1 | |
| SCHEMBL28738831 | 0.84 | PDK1 (0.56) | HSP90AA1HSP90AB1KMT2AMEN1PDK1 | |
| SCHEMBL3327166 | 0.83 | KCNMA1 (0.54) | HSP90AA1HSP90AB1KMT2AMEN1GAA | |
| SCHEMBL29991673 | 0.83 | LMNA (0.56) | KMT2AMEN1GAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| EP-2512478-B1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-04-19 | — | — | EP | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9408907-B2 | Homogenous suspension of immunopotentiating compounds and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-09 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | disclosed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1888538-B1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| EP-1888538-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006117305-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | HSP90AA1 3777/4885HSP90AB1 3637/4885GRIK1 716/4885 |
| US-20160375132-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | CD14, ICOS, CD69 | HSP90AA1 1164/4885HSP90AB1 813/4885GRIK1 3554/4885 |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HTR5A, NPY5R, HTR3A | HSP90AA1 3931/4885HSP90AB1 4196/4885GRIK1 271/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | HSP90AA1 3777/4885HSP90AB1 3637/4885GRIK1 716/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | HSP90AA1 192/4885HSP90AB1 149/4885GRIK1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.